Startup · $14m raised
Developing vaccine candidate targeting P. gingivalis linked to Alzheimer's
Melbourne, VIC
Programs: Brandon BioCatalyst (CUREator)
Every investor coverage indicates participated in a round Denteric raised.
| Investor | Rounds | Invested |
|---|---|---|
| Biomedical Translation Fund | Series A | - |
| Brandon BioCatalyst | Accelerator | - |
| CSL | Series A | - |
| University of Melbourne | Series A | - |
Investors whose own portfolio pages list Denteric, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Brandon Capital | its portfolio page ↗ |
Companies Denteric acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Sean McLoughlin | Chief Executive Officer | Brandon BioCatalyst, Brandon Capital |
Stories naming Denteric. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Profile of Denteric, a biotech developing GPV381, an injectable therapy targeting gum bacteria implicated in Alzheimer's disease; the team is seeking backers to fund its first study in patients.
Brandon Capital's blog interviews Denteric's operating chief about its gingipain-targeting therapy for periodontitis, trial progress, and its origins in University of Melbourne oral health research.
Denteric has begun recruiting early Alzheimer's patients for a Phase I trial of its gingipain-targeting therapy GPV381, with funding from the CUREator+ Dementia program and the Medical Research Future Fund.
Melbourne biotech Denteric has won US regulatory clearance to trial GPV381, a vaccine-style therapy targeting the bacteria behind gum disease, with a Phase 2 study in the United States to follow.
Government-backed CUREator+ program awards non-dilutive funding to seven Australian companies developing dementia and cognitive decline therapeutics, devices and digital health tools.
Brandon BioCatalyst's CUREator incubator names its first-round awardees, distributing government-backed funding across 23 Australian life science companies working on treatments from schizophrenia to diabetes, with round two applications now open.
The CUREator incubator, run by Brandon BioCatalist's partner organisation, names its first-round awardees, distributing government-backed grant funding across 23 Australian life science companies developing treatments for diseases including diabetes, cancer and COPD.
Index of the venture firm's portfolio updates: financing rounds for AdvanCell and ENA Respiratory, grant awards via incubator programs, two closes of Fund Six, board hires, and Myricx Bio's completed sale to Novartis.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Uniseed·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon Capital portfolio·SmartCompany·AFR Technology·Startup Daily·Startup Daily·SmartCompany·Startup Daily·Startup Daily·@AuManufacturing·finance.yahoo.com·enarespiratory.com·Mirage News·advancell.com.au·Forbes Australia·datapile.co·Dealroom·Forbes Australia·datapile.co·Biotech Dispatch·fundedstartupsdaily.com·fundedstartupsdaily.com
Denteric, a biotech spun out of an oral health research program, has raised $14 million for a gum disease vaccine, in a round led by the Biomedical Translation Fund with CSL also taking part.
Also denteric.com